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Background/aim: Bone disease is one of the most prominent complications after kidney transplantation. Bone diseases include
osteoporosis, persistent secondary hyperparathyroidism, and avascular necrosis (AVN). We investigated the relationship between the
polymorphisms of the vitamin D receptor (VDR) gene and bone diseases occurring after kidney transplantation.
Materials and methods: The study consists of 234 kidney allograft recipients with a minimum follow-up of five years after kidney
transplantation. Patients with glomerular filtration rates less than 30 mL/min/1.73m2, a history of parathyroidectomy, bisphosphonate
use pre- or post-transplantation, and cinacalcet use posttransplantation excluded. We evaluated associations between the polymorphisms
of the VDR gene (BsmI, TaqI, ApaI, FokI, and Cdx2), the first-year bone mineral density (BMD) scores, persistent secondary
hyperparathyroidism, and AVN.
Results: Patients with low BMD scores were significantly younger (P = 0.03) and had higher intact parathormone (iPTH) levels (P
= 0.03). Cdx2 TT genotype significantly increases the risk of low BMD scores (OR: 3.34, P = 0.04). Higher phosphate levels were
protective against abnormal BMD scores (OR: 0.53; P = 0.03). Patients with persistent hyperparathyroidism had significantly longer
dialysis vintage and higher pretransplantation iPTH levels (P = 0.02 and P < 0.001, respectively). Cdx2, CT/TT, and ApaI CA/AA
genotypes significantly increase the risk of persistent hyperparathyroidism (OR: 6.81, P < 0.001, OR: 23.32, P < 0.001, OR:4.01, P = 0.02,
and OR: 6.30, P = 0.01; respectively). BsmI CT/TT genotypes were found to increase AVN risk with an HR of 3.48 (P = 0.03). Higher
hemoglobin levels were also found to decrease AVN risk with an HR of 0.76 (P = 0.05).
Conclusion: Certain VDR gene polymorphisms are associated with a higher risk for bone diseases after kidney transplantation.
Key words: Kidney transplantation, VDR polymorphisms, osteoporosis, avascular necrosis, persistent hyperparathyroidism

1. Introduction
Kidney transplantation is the treatment of choice in endstage kidney disease. Most of the chronic kidney disease
(CKD) complications, such as anemia, cardiovascular
mortality, and secondary hyperparathyroidism, tend
to improve after kidney transplantation [1]. However,
similar improvements are not observed in bone health [2].
Osteoporosis secondary to the use of glucocorticoids and
other immunosuppressive drugs after solid organ or stem
cell transplantation is firmly established. However, the
osteoporosis mechanism after kidney transplantation is
much more complicated. CKD – mineral and bone disorder
(MBD) residues and persistent hyperparathyroidism
considerably affect bone health [3,4]. Other suggested risk
factors for osteoporosis after kidney transplantation are

calcium and vitamin D deficiencies, age, female sex, and
specific vitamin D receptor (VDR) polymorphisms (BsmI)
[5,6].
The role in the skeletal metabolism of the steroid
hormone Vitamin D’s nuclear receptor is well known.
The vitamin D receptor (VDR) is a nuclear receptor that
binds to DNA and acts as a transcription factor. The
different receptor regions have distinctive functions,
such as DNA binding, receptor dimerization, gene, and
cofactor activation. The VDR gene consists of the noncoding 5′promoter region, exons 1A, 1B, 1C, exons 2 to
3 encoding the DNA-binding region, and exons 4 and 5
encoding the ligand-binding region. The most known
VDR gene polymorphisms are BsmI (rs1544410), TaqI
(rs731236), ApaI (rs7975232), FokI (rs2228570) and
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Cdx2 (rs11568820). These polymorphisms are associated
with certain clinical outcomes due to their effects on the
receptor structure or mRNA stability.
The most critical MBD improvement in kidney
transplantation patients is the posttransplantation
recovery of secondary hyperparathyroidism [7].
Secondary hyperparathyroidism does not improve in some
patients. Thus, hypercalcemia, bone loss, and parathyroid
hormone-suppressing treatment requirements continue
in these patients. Calcitriol has a direct, suppressive
effect on the parathyroid hormone by binding to the
parathyroid gland’s VDR. CKD patients with VDR gene
polymorphisms (BsmI) reported having relatively severe
secondary hyperparathyroidism [8].
Avascular necrosis (AVN) is another disorder
associated with CKD cases induced by glucocorticoid
use with VDR gene BsmI polymorphisms due to more
severe secondary hyperparathyroidism. AVN limits
further use of glucocorticoid treatment and is a significant
cause of disability. AVN occurs due to the temporary
bleeding disorder of the bone and the reperfusion
process. Angiogenesis is the first recovery phase after
reperfusion. The second recovery phase is the cellular
differentiation of mesenchymal cells to osteoblasts and
osteoclasts. Inadequacy in the second phase causes
significant morbidity. In the VDR knockout mice studies,
VDRs demonstrated a direct cellular effect in osteoblast
formation during bone regeneration [9]. Many studies
investigate the mechanism of AVN susceptibility. However,
AVN’s etiological, genetic, and pathogenic mechanisms
have not been fully elucidated [10].
Vitamin D metabolism is crucial in bone diseases.
This study investigates the possible associations between
bone mineral density (BMD), persistent secondary
hyperparathyroidism, AVN, and VDR gene polymorphisms
(BsmI, TaqI, ApaI, FokI, and Cdx2) in kidney transplant
recipients.
2. Material and methods
2.1. Study design and participants
The study was conducted between January 2018 and
January 2019, with all living or cadaveric kidney allograft
recipients giving informed consent. All recipients had five
or more years of follow-up after their kidney transplantation
in our institute. Patients were excluded who had an
estimated glomerular filtration rate (eGFR) of less than
30 mL/min/1.73m2 as calculated by the Chronic Kidney
Disease Epidemiology Collaboration formula. Other
exclusion criteria were a history of parathyroidectomy, a
history of malignancy, anorexia, malnutrition, and hypoor hyperthyroidism.
Patients’ demographic features, primary renal disease,
dialysis vintage, and comorbid conditions were evaluated.

We recorded the dose and duration of the previous and
current medical treatments. For each subject, we calculated
the lifetime cumulative glucocorticoid dose that included
the pretransplantation period.
2.2. Materials and measurements
The
patients’
laboratory
parameters
of
the
pretransplantation period, first-year posttransplantation,
and simultaneous with AVN, if applicable, were evaluated
retrospectively. Dual-energy x-ray absorptiometry (DXA
Horizon; Hologic Inc., Marlborough, MA, USA) was
used with the unit of g/cm2 to examine the BMD of the
posteroanterior position of the lumbar vertebrae L14, left proximal femoral neck, and total hip. The World
Health Organization (WHO) classification for osteopenia
and osteoporosis in terms of Z and T scores was used to
determine bone health. For premenopausal women and
men under the age of 50, the Z score was considered. For
postmenopausal women and men over the age of 50, the
T score was considered. Z or T score of ≤ –2.5 indicates
osteoporosis. Z or T score between −2.5 and –1.0 indicates
osteopenia. Z or T score of ≥ –1.0 indicates a normal bone
mass [11]. For men under 50 years of age, a Z score < –2 is
considered “below the expected range for age” according
to the International Society for Clinical Densitometry
(ISCD) recommendations [12]. The subjects’ BMD
scores were divided into two groups: Normal BMD and
abnormal BMD (osteopenia or osteoporosis) according
to the femur neck or the lumbar total BMD scores.
Patients with a femoral neck or lumbar total BMD scores
< –1 were included in the abnormal BMD group. The
persistent hyperparathyroidism group consisted of cases
with serum iPTH levels > 65 pg/mL during their firstyear posttransplant [13]. AVN cases were diagnosed using
the x-ray examination, bone scintigraphy, or magnetic
resonance imaging modalities.
2.3. Genotyping
We drew an extra 5 cc of blood from the participants’
antecubital vein during the sampling for one of their
routine controls. We immediately transferred the draws to
EDTA containing tubes. Since the study was carried out on
the stable DNA molecule, blood samples were refrigerated
at –80 °C and studied collectively at the end of the study.
DNA was extracted from whole blood using the Zinexts
MagPurix Extraction Kit (ZP02001) (Zinexts Life Science,
New Taipei City, Taiwan). A pair of polymerase chain
reaction (PCR) primers were designed for each studied
polymorphism. Template sequences are obtained from the
Ensembl database1, and the transcript ID used for the VDR
gene is ENST00000549336 (RefSeq ID: NM_000376).
Primers are designed in-house by using Primer 2.0 software
(Scientific and Educational Software). The primers and the
Ensembl Project (2021). Ensembl Database [online]. Website
http://www.ensembl.org/ [accessed date 00 Month Year].
1
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amplicon sizes obtained from the PCR are shown in Table
1. PCR amplification of the regions was performed using
the designed primers. The PCR conditions are shown in
Table 2. The reaction results were effectively visualized
with a 2% agarose gel electrophoresis. For each sample, the
PCR products were pooled by mixing them approximately
equal with a consideration of the reaction yield. The PCR
pools generated for each sample were purified according
to the manufacturer’s recommended method (MNNucleoFast 96, Macherey-Nagel, Düren, Germany). The
measured and purified PCR pools (Nanodrop-ND1000,
Thermo Fisher Scientific,Waltham, MA, USA) were set
to 0.2 ng/µL in accordance with the sequencing kit used.
The next-generation sequence was performed using the
Miseq device of Illumina, California, USA. The samples
were analyzed, and the genotypes were identified using the
Table 1. The primers and the amplicon sizes.
Amplicon
size (bp)

Primers Sequence (5’->3’)
Cdx 2
Forward
Cdx 2
Reverse
FokI
Forward
FokI
Reverse
BsmI
Forward
BsmI
Reverse
ApaI
and TaqI
Forward
ApaI
and TaqI
Reverse

GGAATGAAAGAGGGAAGGAGGGAG
CTGTAGCAATGAAAGCAAACCAAGG
CACTGACTCTGGCTCTGACCGTG
CAGCCTTCACAGGTCATAGCATTG
ACTGCCCTTAGCTCTGCCTTGC
AAGGGTCACTGCACATTGCCTC

215

177

259

CAGGCAGTGGTATCACCGGTCAG
292
CGGCTAGCTTCTGGATCATCTTGG

Table 2. The polymerase chain reaction conditions.
Content

Amount per Reaction (µL)

15
dH20
5x Tampon (Thermo Fisher
5
Scientific Inc.,Waltham, MA, USA)
dNTP mixture, each 10 mM
0.5
Forward Primer (5 µM)

1

Reverse Primer (5 µM)
Phire II HS DNA Polymerase
(Thermo Fisher Scientific Inc.)
Bar DNA (20–50 ng/µL)

1

Total

25

804

0.5
2

Miseq Reporter software from Illumina Inc. (San Diego,
CA, USA) and the IGV 2.3 software developed by Broad
Institute (California, USA).
The study group’s genotypic distributions were
analyzed according to their ages and their cumulative
glucocorticoid doses. Considering the BMD scoring, we
set the age cut-off to 50 years according to the WHO and
ISCD recommendations. We set the cut-off value of the
cumulative glucocorticoid dose to the study population’s
mean dose. Compound heterozygosities were expressed
as the percentage of the coexistence of the heterozygous
or homozygous mutant type of other polymorphisms in
heterozygous cases for each polymorphism.
2.4. Statistical methods
The numeric values are shown with the mean, standard
deviation, medians with ranges, categorical data,
frequencies, and percentages. We used the unpaired
Student’s t-test to compare two groups for the data
normally disturbed and independent samples t-test to
compare more than two groups, and for the VDR gene
polymorphism distributions’ frequency comparisons. We
compared the categorical variables with chi-square test
or Fisher’s exact test where applicable. We performed the
Mann–Whitney U Test for the nonnormally distributed
data. For the multivariate analysis, the possible factors
identified with the univariate analyses were further entered
into the logistic and Cox regression analyses. These factors
were entered with the backward selection to determine
the independent patient outcome predictors. The logistic
regression was used for the first-year posttransplantation
BMD scores and hyperparathyroidism. The Cox
regression was used for AVN. A P value of less than 0.05
was considered statistically significant. We performed
statistical analyses using the Statistical Package for Social
Science (SPSS) (IBM Corp., Armonk, NY, USA) for
personal computers version 21.0.
3. Results
3.1. Power analysis
Power analysis was performed using the G*Power Statistical
Software according to the wild (CC) and mutant (CT &
TT) types of the VDR gene CDX2 polymorphism. The
calculated power (1 – β) is 0.953. This value is calculated
using the type I error (α) of 0.05, the total sample size of
234, the effect size of 0.48, and the two-sided alternative
hypothesis (H1).
3.2. Osteopenia and osteoporosis
The baseline characteristics and VDR genotype
distribution of patients are presented in Table 3. Patients
with low BMD scores were significantly younger (P =
0.03). Cyclosporin-A (CsA) use was significantly frequent
in the abnormal BMD group (P = 0.04). The patients
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Table 3. Baseline characteristics of patients grouped according to posttransplant first year BMD scores.
Normal BMD
(n = 153)
42.1 (±12.9)

Abnormal BMD
(n = 81)
38.5 (±12.2)

57/96
Unknown: 69
Gn/Vasc: 26
DM: 17
Others: 41
19 (12.4%)

31/50
Unknown: 34
Gn/Vasc: 18
DM: 8
Others: 21
6 (7.4%)

0.07

22 (0–228)
Tac: 52 (64.1%)
CsA: 13 (16.0%)
Eve: 4 (4.9%)
Sir: 6 (7.4%)
3460.9 (±808.3)

0.90

Steroid, mg mean (±SD)

19 (0–242)
Tac: 131 (85.6%)
CsA: 18 (11.7%)
Eve: 9 (5.8%)
Sir: 10 (6.5%)
3525.7 (±1050.3)

eGFR mean (±SD)

74.3 (±25.0)

75.6 (±24.5)

0.12

Ca, mmol/L mean (±SD)

2.38 (±0.15)

2.35 (±0.13)

0.68

P, mmol/L mean (±SD)

1.03 (±0.19)

1.00 (±0.16)

0.08

Mg, mmol/L mean (±SD)

0.85 (±0.10)

0.90 (±0.15)

0.60

25-OH-D, nmol/L mean (±SD)

80.6 (±28.2)

81.1 (±29.4)

0.65

Pre Tx iPTH, ng/L med (min-max)

600.2 (60.4–2853.2)

612.0 (128.1–1981.8)

0.95

1st year iPTH, ng/L med (min-max)

64.3 (14.5–2249.7)

71.4 (26.9–950.9)

0.03

LDL, mmol/L mean (±SD)

2.72 (±0.85)

2.68 (±0.93)

0.22

TG, mmol/L mean (±SD)

1.64 (±0.87)

1.67 (±0.94)

0.43

Cdx2 CC/CT/TT (%)

65.4/28.7/5.9

55.6/34.6/9.8

0.04

Fok1 AA/AG/GG (%)

7.2/43.1/49.7

12.3/42.0/45.7

0.31

Bsm1 CC/CT/TT (%)

40.5/47.7/11.8

28.4/34.6/37.0

0.04

Apa1 CC/CA/AA (%)

25.5/43.8/30.7

16.0/33.3/50.7

0.17

Taq1 AA/AG/GG (%)

43.8/45.7/10.5

30.8/34.6/34.6

0.10

Age mean (±SD)
Sex, F/M (n)
Disease (n)
DM, n (%)
Vintage, (month) med (min-max)
CNI, n (%)
mTORi, n (%)

P value
0.03

0.12
0.09
0.04
0.31
0.94

SD: Standard deviation, BMD: Bone mineral density, F/M: Female/Male, Disease: Primary renal disease, Gn/Vasc: Glomerulonephritis
or systemic vasculitis, DM: Diabetes mellitus, Vintage: Dialysis vintage, med: Median, CNI: Calcineurin inhibitors, Tac: Tacrolimus,
CsA: Cyclosporine-A, mTORi: Mammalian target of rapamycin inhibitors, Eve: Everolimus, Sir: Sirolimus, Steroid: Cumulative
steroid dose, eGFR: estimated glomerular filtration rate (mL/min/1.73m2), Ca: Calcium, P: Phosphate, Mg: Magnesium, 25-OH-D:
25-hydroxyvitamin D, Tx: Transplantation, iPTH: intact Parathormone, LDL: Low-density lipoprotein cholesterol, TG: Triglyceride.

with low first-year posttransplantation BMD scores had
significantly higher simultaneous intact Parathormone
(iPTH) levels (P = 0.03). The distribution of sex and primary
diseases; the frequency of diabetics and mammalian target
of rapamycin inhibitor (mTORi) users; dialysis vintage,
cumulative doses of steroids, and laboratory parameters
other than posttransplantation first-year iPTH levels were
all similar between the study groups.
The VDR gene’s Cdx2 TT genotype significantly
increases the risk of low BMD scores with an odds ratio
(OR) of 3.34 (min: 1.04 – max: 10.75; P = 0.04) when
corrected for all possible risk factors. The higher serum
phosphate levels were found to be protective against
abnormal BMD scores (OR: 0.53, min: 0.30 – 0.95; P =
0.03), as demonstrated in Table 4.

3.3. Persistent hyperparathyroidism
The patients’ baseline characteristics and VDR genotype
distribution are presented in Table 5. The patients with
persistent hyperparathyroidism had a significantly longer
dialysis vintage and high pretransplantation iPTH levels
(P = 0.02 and P < 0.001, respectively). The calcium and
alkaline phosphatase levels were significantly high in the
persistent hyperparathyroidism group (P = 0.004 and P
< 0.001, respectively) (Table 5). The distribution of age
and sex were similar between groups. The levels of eGFR,
phosphate, magnesium, and 25-OH-D vitamin were also
similar between groups.
The Cdx2 CT and TT genotypes of the VDR
gene significantly increases the risk of persistent
hyperparathyroidism [OR: 6.81 (min: 3.16 – max: 14.69), P
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Table 4. Logistic regression analysis of risk factors for low BMD
scores.
OR (95% CI)

P value

CT

1.77 (0.88-3.55)

0.10

TT

3.34 (1.04–10.75)

0.04

AG

0.90 (0.30–2.68)

0.85

GG

0.72 (0.24–2.13)

0.55

CT

0.54 (0.09–3.03)

0.48

TT

2.42 (0.12–45.70)

0.55

CA

1.69 (0.58–4.19)

0.33

AA

1.99 (0.49–8.08)

0.33

AG

0.96 (0.19–4.76)

0.96

GG

1.06 (0.07–15.67)

0.96

Age

0.97 (0.95–1.00)

0.93

Sex (Male)

1.03 (0.50–2.11)

0.93

Vintage (month)

1.02 (0.93–1.13)

0.57

Cdx2 (ref: CC)
FokI (ref: AA)
BsmI (ref: CC)
ApaI (ref: CC)
TaqI (ref: AA)

Pre Tx iPTH (ng/L)

0.99 (0.99–1.00)

0.17

1st year iPTH (ng/L)

1.00 (0.99–1.00)

0.63

25-OH-D (nmol/L)

1.00 (0.97–1.03)

0.72

Ca (mmol/L)

0.64 (0.36–1.14)

0.13

P (mmol/L)

0.53 (0.30–0.95)

0.03

Mg (mmol/L)

0.43 (0.11–1.63)

0.21

eGFR

0.99 (0.98–1.01)

0.66

Steroid (mg)

1.00 (0.99–1.00)

0.49

Tac

0.64 (0.07–5.31)

0.68

CsA

0.41 (0.16–1.05)

0.06

Eve

1.32 (0.20–8.53)

0.76

Sir

0.78 (0.12–5.07)

0.80

OR: Odds ratio.

< 0.001, and OR: 23.32 (min: 3.16 – max: 14.69), P < 0.001;
respectively] when corrected for all possible risk factors.
The CA and AA genotypes of ApaI also increase the risk
of persistent hyperparathyroidism [O.R.: 4.01 (min: 1.24
– max: 112.95), P = 0.02, and O.R.: 6.30 (min: 1.45 – max:
27.42), P = 0.01; respectively] (Table 6).
3.4. Avascular necrosis
Table 7 demonstrates the patients’ baseline characteristics
and VDR genotype distribution. Twenty-one subjects
experienced AVN with a median of 85 months (min: 5 –
max: 489). All patients had a minimum follow-up time
of five years. Before the event, the patients with AVN had
a cumulative steroid dose median of 5717.5 mg (min:
2752.5 – max: 56,490.0). The patients without AVN had a
significantly higher cumulative steroid dose [12637.5 mg
(min: 2605.0 – max: 79,250.5), P = 0.002] than the patients
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with AVN. Antiaggregant use was frequent in patients
without AVN (P = 0.04). The patients’ hemoglobin levels
were significantly lower in AVN patients than those without
AVN (P = 0.03) (Table 7). The distribution of age, sex,
primary diseases, and frequency of diabetics were similar
between the groups. The CNI, mTORi, antilipidemic agent
users, dialysis vintage, and laboratory parameters other
than hemoglobin levels were also similar.
The VDR gene’s BsmI CT or TT genotypes were found
to increase the AVN risk with an HR of 3.48 (min: 1.11
– max: 10.42, P = 0.03). Higher hemoglobin levels were
found to decrease the AVN risk with a hazard ratio (HR) of
0.76 (min: 0.58 – max: 0.99, P = 0.05), as shown in Table 8.
3.5. Genotype distributions according to age and
cumulative glucocorticoid doses and compound
heterozygosity of the population
The distribution of Cdx2, Fok1, Bsm1, Apa1, and
Taq1 polymorphisms according to age and cumulative
glucocorticoid doses are shown in Table 9. The
distributions of polymorphisms were similar in the groups
under and above 50 years of age and among the groups
receiving treatment below and above the mean cumulative
glucocorticoid dose of the study population.
Table 10 shows compound heterozygosity percentages
of the study population. 70.8% of the cases with Cdx2
heterozygous polymorphism also carried a mutant
ApaI polymorphism. All cases with BsmI heterozygous
polymorphism also carried an additional mutation.
4. Discussion
The current immunosuppression protocols after kidney
transplantation provide a better graft survival but cause
many complications that prominently impact bone health.
The possibility of patients developing bone diseases with
similar demographics, clinical features, or treatment
protocols cannot be estimated. This is despite the significant
factors of dialysis vintage, cumulative glucocorticoid dose,
and age. This study investigated the essential VDR gene
polymorphisms in a large kidney transplant recipient
population and their significance within five or more years
of follow-up.
The VDR is a 427-amino acid protein. The VDR gene is
located on the long arm of chromosome 12 at position 13.11
(12q13.11). The gene consists of 11 exons [14]. The Cdx2
promoter polymorphism plays a role in the VDR gene’s
intestinal-specific transcription. The G allele reduces VDR
transcriptional activity relative to the A allele influencing
its calcium absorption. The FokI polymorphism is located
in the VDR gene exon 2 and plays an essential role in the
VDR protein’s posttranscriptional modifications. The
BsmI, ApaI, and TaqI polymorphisms are located in the
3’-regulatory region and are suggested to impact mRNA
stability [15].
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Table 5. Baseline characteristics of patients grouped according to the first-year posttransplant parathormone levels.
Resolved hyperparathyroidism
(n = 161)

Persistent hyperparathyroidism
(n = 73)

P value

Age mean (±SD)

41.2 (±13.0)

40.6 (±12.2)

0.54

Sex F/M (n)

57/104

31/42

0.08

Vintage, (month) med (min-max)

42 (0–221)

52 (0–248)

0.02

eGFR mean (±SD)

74.5 (±24.3)

75.2 (±26.2)

0.34

Ca, mmol/L mean (±SD)

2.35 (±0.16)

2.49 (±0.17)

0.004

P, mmol/L mean (±SD)

1.03 (±0.16)

1.00 (±0.19)

0.72

Mg, mmol/L mean (±SD)

0.85 (±0.10)

0.85 (±0.11)

0.97

25-OH-D, nmol/L mean (±SD)

81.4 (±29.7)

79.4 (±25.9)

0.44

Pre Tx iPTH, ng/L med (min-max)

470.2 (60.2–2755.1)

745.1 (132.1–2340.0)

<0.001

ALP, µkat/L mean (±SD)

1.38 (±0.48)

1.63 (±0.93)

<0.001

Cdx2 CC/CT/TT (%)

74.5/23.0/2.5

34.3/47.9/17.8

<0.01

Fok1 AA/AG/GG (%)

8.1/47.2/44.7

11.0/32.9/56.1

0.21

Bsm1 CC/CT/TT (%)

36.6/44.8/18.6

35.6/39.7/24.7

0.56

Apa1 CC/CA/AA (%)

24.8/40.4/34.8

16.4/39.8/43.8

0.86

Taq1 AA/AG/GG (%)

41.0/42.2/16.8

35.6/41.1/23.3

0.95

ALP: Alkaline phosphatase.

Glucocorticoids are the critical agents in bone mineral
loss. The majority of mineral bone loss secondary to
glucocorticoids occurs within the first year of treatment.
Even with high BMD scores, this bone loss poses a greater
bone fracture risk than postmenopausal osteoporosis [16].
In our study, the main differences between the normal and
abnormal BMD groups with osteopenia or osteoporosis
were the age, frequency of calcineurin inhibitor use, and
first-year posttransplantation iPTH levels. The patients
with abnormal BMD scores were significantly younger
than the age mean. The reason for an abnormal BMD
may be that younger patients receive more intense and
prolonged glucocorticoid treatment and CNIs when their
primary kidney disease diagnosis is glomerulonephritis or
vasculitis. It is unknown if patients who underwent these
therapies for their primary kidney disease also accessed
such bone-sparing measures as vitamin D-calcium
supplementation and DEXA monitoring. The subjects
using CsA were a majority in the abnormal BMD group.
The previous studies demonstrated that the CsA alone
or with steroids increases a patient’s osteoporosis risk [5,
17–19].
It was not pretransplantation, but the first-year
posttransplantation iPTH levels were significantly higher
in the abnormal BMD group. With the exception of age,
the differences between the groups lost their significance

in the regression analysis for an abnormal BMD risk.
The VDR gene’s homozygous Cdx2 polymorphism was
associated with a 3.34 fold increase in the abnormal firstyear BMD scores’ risk. The high serum phosphorus levels
in the first-year posttransplantation were significantly
protective of the low BMD scores.
The relationship between the VDR gene polymorphisms
and osteoporosis was mainly studied in postmenopausal
women. FokI, BsmI, and ApaI polymorphisms are
associated with postmenopausal osteoporosis in several
studies, but metaanalyses contradict these studies [20, 21].
The predisposition to postmenopausal osteoporosis caused
by TaqI polymorphism is controversial. The potential
origin of such controversy is because TaqI polymorphism
is a silent polymorphism. It does not cause an amino acid
change in contrast to BsmI and ApaI polymorphisms [15].
No comprehensive studies exist with Cdx2 polymorphism.
More importantly, studies on kidney transplant recipients
are limited. Postmenopausal osteoporosis has a diverse
population and conditions. Lower BMD results were
observed in the younger renal transplant recipients in the
study of Özel et al. [6]. Although the age factor lost its
significance in the regression analysis, similar findings were
found in our study. In the same study, BsmI polymorphisms
were frequent in patients with osteoporosis after kidney
transplantation, but a regression analysis was not applied.
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Table 6. Logistic regression analysis of risk factors for persistent
hyperparathyroidism.
OR (95% CI)

P value

CT

6.81 (3.16–14.69)

<0.001

TT

23.32 (5.8–92.23)

<0.001

AG

0.35 (0.11–1.12)

0.07

GG

0.57 (0.18–1.77)

0.33

CT

0.10 (0.01–0.99)

0.06

TT

0.10 (0.01–3.48)

0.20

CA

4.01 (1.24–12.95)

0.02

AA

6.30 (1.45–27.42)

0.01

AG

4.12 (0.49–34.06)

0.18

GG

4.02 (0.15–106.21)

0.40

Age

0.99 (0.96–1.02)

0.89

Vintage (month)

1.02 (0.93–1.13)

0.57

Pre Tx iPTH (ng/L)

1.07 (0.96–1.18)

0.18

25-OH-D (nmol/L)

0.99 (0.96–1.02)

0.51

Ca (mmol/L)

1.67 (0.90–3.08)

0.99

P (mmol/L)

0.79 (0.45–1.40)

0.43

Mg (mmol/L)

1.16 (0.30–4.51)

0.82

eGFR

0.98 (0.96–1.00)

0.11

Cdx2 (ref: CC)

FokI (ref: AA)

BsmI (ref: CC)

ApaI (ref: CC)

TaqI (ref: AA)

In our study, BsmI was not a significant risk factor in the
regression analysis when corrected with essential clinical
factors for osteoporosis.
When
the
subjects
were
evaluated
in
hyperparathyroidism at the end of the first year of
transplantation, the persistent hyperparathyroidism
group had a longer dialysis vintage. We found the
pretransplantation iPTH levels to be significantly
higher. In the regression analysis, these findings lost
their significance. The risk of first-year abnormal
BMD scores was increased 6.81 times by heterozygous
Cdx2 polymorphism, 23.32 times by homozygous
Cdx2 polymorphism, 4.01 times by heterozygous ApaI
polymorphism, and 6.30 times by homozygous ApaI
polymorphism. Several studies investigated the VDR
polymorphisms with hyperparathyroidism secondary
to CKD. The study results were contradictory when
examining the relationship between BsmI polymorphism
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and secondary hyperparathyroidism [8, 22–25]. FokI
polymorphism was associated with higher iPTH values in
dialysis patients [26].
The most unpredictable of all posttransplant bone
complications is AVN. The leading risk factor for AVN
is the use of glucocorticoids. However, the predictive
value of the treatment duration and cumulative doses of
glucocorticoids are controversial [27–29]. The studies
investigating an AVN susceptibility have generally
included coagulation cascade-associated genes [30]. Two
studies investigated the risk of FokI polymorphisms on
AVN development in pediatric leukemia patients but
found conflicting results with each other [31]. When our
study population with a minimum follow-up period of five
years was evaluated, the cumulative dose of glucocorticoid
treatment was significantly lower, and the duration of
glucocorticoid use was significantly shorter in patients
who developed AVN. When corrected by all proposed risk
factors, the presence of BsmI heterozygous or a homozygous
polymorphism of the VDR gene increased the risk of AVN
by 3.48 times. Also, the higher hemoglobin levels were
found to be protective against AVN development. The
relationship between hemoglobin and AVN was mainly
investigated in patients with sickle cell disease, and an
association between anemia and AVN was shown [32].
Narayanan et al. reported significantly lower hemoglobin
levels in nonsickle cell disease patients with AVN. These
results are consistent with the findings in our study [33].
In this respect, the higher hemoglobin levels may increase
the bone’s oxygenation and demonstrate a protective
effect. Anemia control of kidney transplantation recipients
may be crucial for protection from AVN. However, the
regression analysis revealed that the glucocorticoid
treatment’s cumulative dose or duration was not associated
with an AVN risk.
Other observations in this study are that although not as
severe as the mutant types, heterozygous variants of Cdx2
and ApaI polymorphisms and the heterozygous variant of
BsmI is also associated with an increased risk of persistent
secondary hyperparathyroidism and AVN; respectively.
Compound heterozygosity is the condition of having two
or more heterozygous or mutant alleles at a particular
locus that can cause genetic disease in a heterozygous state
[34]. We observed that the coexistence of heterozygous
VDR gene mutations in our study population is relatively
high. An ApaI mutation was detected in 70.8% of Cdx2
heterozygous cases, and an additional mutation was
detected in all of the BsmI heterozygous cases. In this
context, it is impossible to say whether the BsmI mutation
itself is a risk factor or poses a risk due to accompanying
mutations. Studies with larger populations are necessary
to elucidate the risks of compound heterozygosity in this
patient population.
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Table 7. Baseline characteristics of patients with or without AVN.
No AVN
(n = 213)
41.0 (±12.9)

AVN
(n = 21)
40.5 (±11.5)

81/132
Unknown: 81
Gn/vasculitis: 38
Dm: 25
Others: 69
25 (11.7%)

7/14
Unknown: 11
Gn/vasculitis: 6
Dm: 0
Others: 4
0 (0%)

0.33

52.1 (0–231)
Tac: 14 (66.6%)
CsA: 5 (23.8%)
Eve: 0 (0%)
Sir: 2 (9.5%)
5717.5 (2752.5–56490.0)

0.59

Steroid, mg mean (±SD)

45.6 (0–238)
Tac: 172 (80.7%)
CsA: 22 (10.3%)
Eve: 13 (6.1%)
Sir: 8 (3.7%)
12637.5 (2605.0–79250.5)

Steroid duration (month) med (min-max)

84 (60–325)

34 (2–201)

<0.001

Antilipidemic n (%)

16 (7.5%)

0 (0%)

0.99

Antiaggregant n (%)

21 (9.8%)

1 (4.7%)

0.04

eGFR mean (±SD)

75.3 (±24.9)

68.8 (±23.6)

0.25

Ca, mmol/L mean (±SD)

2.38 (±0.15)

2.38 (±0.17)

0.92

P, mmol/l mean (±SD)

1.03 (±0.16)

1.00 (±0.19)

0.67

Mg, mmol/L mean (±SD)

0.85 (±0.15)

0.90 (±0.10)

0.78

25-OH-D, nmol/L mean (±SD)

79.6 (±28.7)

90.6 (±25.7)

0.71

Pre Tx iPTH, ng/L med (min-max)

573.5 (60.7–2854.2)

733.1 (141.2–2293.0)

0.06

1st year iPTH, ng/L med (min-max)

67.3 (17.5–2249.2)

53.2 (14.0–279.9)

0.16

Hb, g/L mean (±SD)

127.2 (±21.2)

120.1 (±16.1)

0.03

Alb, g/L mean (±SD)

43.2 (±4.0)

42.4 (±3.2)

0.72

LDL, mmol/L mean (±SD)

2.73 (±0.89)

2.54 (±0.66)

0.13

TG, mmol/L mean (±SD)

1.64 (±0.91)

1.55 (±0.74)

0.60

Follow-up (year) med (min-max)

7.0 (5.0–27.1)

9.0 (5.0–23.1)

0.14

Cdx2 CC/CT/TT n (%)

60.6/31.9/7.5

75.3/19.2/5.5

0.04

Fok1 AA/AG/GG n (%)

9.9/41.8/48.3

0.0/50.0/50.0

0.12

Bsm1 CC/CT/TT n (%)

37.6/41.3/21.1

27.3/59.1/13.6

0.03

Apa1 CC/CA/AA n (%)

23.0/38.0/39.0

18.2/59.1/22.7

0.02

Taq1 AA/AG/GG n (%)

40.4/40.4/19.2

31.9/54.5/13.6

0.09

Age mean (±SD)
Sex F/M (n)
Disease (n)
DM, n (%)
Vintage, (month) med (min-max)
CNI, n (%)
mTORi, (n)

P value
0.68

0.24
0.09
0.09
0.94
0.002

AVN: Avascular necrosis, Hb: Hemoglobin, Alb: Albumin.

The study’s limitation is that although the number
of patients is large, it is single centered. Multicenter
and multinational studies will determine the subject’s
availability in clinical practice. If supported by subsequent
studies, the immunosuppressive agents’ management
after transplantation and bone health measures can be
individualized.
5. Conclusion
Bone diseases are one of the significant morbidities after
kidney transplantation. The bone diseases that affect

kidney transplant recipients are osteoporosis and AVN.
Both osteoporosis and AVN cause significant, longterm morbidity. Kidney transplant recipients are also
indefensible to persistent hyperparathyroidism because
of their longstanding history of CKD. This increases the
complexity of the evaluation and the treatment of mineral
and bone disorders. This study suggests that VDR gene
polymorphisms are relevant in patients’ bone health
after kidney transplantation. If these polymorphisms are
studied in a more extensive series, and similar findings
are detected, they will help identify high-risk patients.
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Table 8. Cox regression analysis of risk factors for avascular
necrosis.
HR (95% CI)

P value

Cdx2 (ref: CC) CT or TT 0.40 (0.13–1.17)

0.09

FokI (ref: AA)

0.84

AG or GG 0.99 (0.44–3.44)

BsmI (ref: CC) CT or TT 3.48 (1.11–10.42) 0.03
ApaI (ref: CC)

CA or AA 0.73 (0.04–12.99)

TaqI (ref: AA)

0.83

AG or GG 0.52 (0.03–9.02)

0.65

Steroid (mg)

1.00 (0.99–1.00)

0.01

Vintage (month)

0.91 (0.74–1.14)

0.43

25-OH-D (nmol/L)

1.04 (1.01–1.08)

0.01

Hb (g/L)

0.76 (0.58–0.99)

0.05

LDL (mmol/L)

0.99 (0.97–1.01)

0.35

HR: Hazard ratio.
Table 9. VDR polymorphism distributions according to age and cumulative steroid dose.
Age <50
103(58.9%)
56(32%)
16(9.1%)
18 (10.3%)
Fok1 AA/AG/GG (%) 70 (40%)
87 (49.7%)
64 (36.6%)
Bsm1 CC/CT/TT (%) 74 (42.3%)
37 (21.1%)
36 (20.6%)
Apa1 CC/CA/AA (%) 72 (41.1%)
67 (38.3%)
68 (38.9%)
Taq1 AA/AG/GG (%) 74 (42.3%)
33 (18.8%)
Cdx2 CC/CT/TT (%)

Age ≥50

P value

39 (66.2%)
16 (27.1%)
4 (6.7%)
3 (5.1%)
30 (50.8%)
26 (44.1%)
21 (35.6%)
27 (45.8%)
11 (18.6%)
16 (27.1%)
22 (37.3%)
21 (35.6%)
24 (40.7%)
24 (40.7%)
11 (18.6%)

0.06
0.12
0.66
0.73
0.89

Lower cumulative
steroid*
47 (55.3%)
32 (37.6%)
6 (7.1%)
7 (8.2%)
35 (41.2%)
43 (50.6%)
36 (42.4%)
30 (35.3%)
19 (22.3%)
24 (28.2%)
30 (35.3%)
31 (36.5%)
39 (45.9%)
28 (32.9%)
18 (21.2%)

Higher cumulative
steroid*
98 (65.8%)
40 (26.8%)
11 (7.4%)
14 (9.4%)
65 (43.6%)
70 (47%)
49 (32.9%)
71 (47.7%)
29 (19.4%)
28 (18.8%)
64 (43%)
57 (38.2%)
53 (35.6%)
70 (47%)
26 (17.4%)

*According to the mean cumulative steroid dose of 15,550 mg of the study population.
Table 10. VDR gene compound heterozygosity of the study population.

Cdx2 (CT/TT)

Heterozygous cases
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Additional mutations (%)
FokI
BsmI
(AG/GG)
(CT/TT)
Cdx2 CT (n = 72) 90.3%

ApaI
(CA/AA)
58.3%

TaqI
(AG/GG)
70.8%

58.3%

FokI AG (n = 100) 35%

-

66%

75%

61%

BsmI CT (n = 101) 37.6%

93%

-

100%

100%

ApaI CA (n = 94) 36.1%

92.5%

69.1%

-

68%

TaqI AG (n = 98)

91.8%

97.9%

100%

-

37.7%

P value
0.52
0.93
0.07
0.34
0.06

KORUCU et al. / Turk J Med Sci
Necessary measures can be taken for these patients by
focusing on and tailoring their therapy accordingly.
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